Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mourad Abouelleil

Urology West Palm Beach, FL Medical Doctor

NPI 1225357973 CMS profile 2561526

1411 N Flagler Dr Ste 3800, West Palm Beach, FL 33401

Open in the dashboard

General payments

$4,345

64 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mourad Abouelleil of West Palm Beach, FL is reported in the CMS Open Payments database as having received $4,345 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,569 25
2024 General $1,686 13
2023 General $279 4
2021 General $337 14
2020 General $360 5
2019 General $114 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mourad Abouelleil
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Mourad Abouelleil were reported at $1,569. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Mourad Abouelleil Urology median Middle half National median
2019 $114 $480 $147–$1,201 $163
2020 $360 $246 $87–$645 $114
2021 $337 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $279 $560 $168–$1,461 $160
2024 $1,686 $563 $170–$1,464 $164
2025 $1,569 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. PROCEPT BioRobotics Corporation $1,818 12 payments
  2. Boston Scientific Corporation $870 22 payments
  3. Dornier MedTech America, Inc $245 1 payment
  4. Coloplast Corp $175 4 payments
  5. Ethicon US, LLC $144 2 payments
  6. Olympus America Inc. $143 3 payments
  7. Agiliti Surgical, Inc. $123 1 payment
  8. NeoTract Inc. $122 1 payment
  9. Medtronic, Inc. $113 4 payments
  10. GlaxoSmithKline, LLC. $110 1 payment
  11. Other $482 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,510 62 payments
  2. Travel and Lodging $836 2 payments
Products named General payments · program years 2019–2025
  1. AQUABEAM SYSTEM $1,187 4 payments
  2. AQUABEAM ROBOTIC SYSTEM $632 8 payments
  3. Dornier MedTech $245 1 payment
  4. rezum Generator $218 2 payments
  5. SpaceOAR VUE System - 10mL $191 4 payments
  6. Altis $166 2 payments
  7. VISTASEAL $144 2 payments
  8. Sonablate HIFU $123 1 payment
  9. UROLIFT $122 1 payment
  10. GREENLIGHT $119 1 payment
  11. Other $1,474 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,605

Median for Urology: 1,053

Drug cost

$96,160

Median for Urology: $101,464

Branded share of claims

13%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 49 $62,964
Tamsulosin Hcl Generic 834 $10,174
Solifenacin Succinate Generic 64 $4,902
Tolterodine Tartrate Er Tolterodine Tartrate Brand 26 $3,388
Fosfomycin Tromethamine Generic 11 $2,583
Testosterone Cypionate Generic 64 $2,375
Finasteride Generic 151 $1,866
Potassium Citrate Er Potassium Citrate Brand 20 $1,310
Alfuzosin Hcl Er Alfuzosin Hcl Brand 37 $1,153
Tadalafil Generic 19 $1,023

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$124,943

Medicare's payments for the services billed

Medicare patients

710

Average age 75

Services billed

1,361

82 women, 628 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 39%
Ischemic heart disease 38%
Chronic kidney disease 36%
Cancer 27%
Atrial fibrillation 22%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record